Tirofiban hydrochloride monohydrate CAS NO.150915-40-5
- FOB Price: USD: 25.00-30.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
98%(1-5)Gram98%(5-10)Gram
- Product Details
Keywords
- 150915-40-5
- Cardiovascular Agents
- Pharmaceuticals
Quick Details
- ProName: Tirofiban hydrochloride monohydrate
- CasNo: 150915-40-5
- Molecular Formula: C22H39ClN2O6S
- Appearance: white powder
- Application: Cardiovascular Agents
- DeliveryTime: Shipped in 15 days after payment
- PackAge: according to customers' requirements
- Port: China main port
- ProductionCapacity: 100 Kilogram/Month
- Purity: 98%
- Storage: -20°C Freezer
- Transportation: International express delivery
- LimitNum: 1 Gram
Superiority
About us
Our company has been in existence for 10 years since its establishment. We have our own unique team. The company integrates independent research and development, production and sales. We have established famous brands at home and abroad. At present, our customers have spread all over the world, we have rich Transportation experience, we aim to serve customers, to help customers, solve problems for customers. Look forward to working with you!
Details
Product name
Tirofiban hydrochloride monohydrate CAS:150915-40-5
Packaging, Storage &Shelf Life
Package
1kg/bag,25kg/ drum
Storage
Stored in original packaging for two years at a temperature not exceeding 40°C.
Shelf life
2 years if sealed and stored properly.
Specification
Item |
Specification |
Specific rotation |
+39.5 to +41.5° |
State of solution(transmittance) |
Clear 98.0% min. |
Chloride[cl] |
0.020% max. |
Ammonium [NH4] |
0.02% max. |
Sulfate[SO4] |
0.020% max |
Iron[Fe] |
10ppm max. |
Heavy metals [Pb] |
10ppm max |
Arsenic[As2O3] |
1ppm max |
Other amino acids |
Chromatographically not detectable |
Loss on drying |
0.20% max. |
Residue on ignition[sulfated] |
0.10% max. |
Assay |
99.0% min |
Function
Tirofiban hydrochloride, a chemical name, the English name for Tirofiban Hydrochloride, white powder for angina or non-Q-wave myocardial infarction in patients with unstable angina and the like. Prevention of cardiac ischemic events, but also for patients with coronary ischemic syndromes undergoing coronary angioplasty or coronary atherectomy, and after treatment to prevent sudden coronary occlusion related to ischemic heart complications.